NASDAQ:WVE

Wave Life Sciences Stock Forecast, Price & News

$9.21

+0.20 (+2.22 %)

(As of 11/25/2020 12:00 AM ET)

Add

Compare

Today's Range

$8.99

Now: $9.21▼

$9.55

50-Day Range

$6.99

MA: $8.13▼

$9.14

52-Week Range

$6.61

Now: $9.21▼

$39.98

Volume848,591 shs

Average Volume774,706 shs

Market Capitalization$449.25 million

P/E RatioN/A

Dividend YieldN/A

Beta0.35

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Wave Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.14, Wave Life Sciences has a forecasted upside of 107.8% from its current price of $9.21.
Amount of Analyst Coverage
Wave Life Sciences has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Wave Life Sciences has received 323 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Wave Life Sciences has received 283 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Wave Life Sciences has received 53.30% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote “Outperform” if you believe WVE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Wave Life Sciences does not currently pay a dividend.
Dividend Growth
Wave Life Sciences does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,500,000.00 in company stock.
Percentage Held by Insiders
38.20% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.67% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Wave Life Sciences are expected to grow in the coming year, from ($3.90) to ($1.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Wave Life Sciences is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Wave Life Sciences is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Wave Life Sciences has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.82 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:WVE

Previous Symbol

CUSIPN/A

CIK1631574

Webwww.wavelifesciences.com

Phone65-6236-3388

Employees301

Debt

Debt-to-Equity RatioN/A

Current Ratio1.33

Quick Ratio1.33

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$15.98 million

Price / Sales28.11

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.86 per share

Price / Book4.95

Profitability

EPS (Most Recent Fiscal Year)($5.72)

Net Income$-193,640,000.00

Net Margins-1,562.01%

Return on Equity-401.32%

Return on Assets-72.82%

Miscellaneous

Outstanding Shares48,778,000

Market Cap$449.25 million

Next Earnings Date3/1/2021 (Estimated)

OptionableOptionable

$9.21

+0.20 (+2.22 %)

(As of 11/25/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions

How has Wave Life Sciences' stock been impacted by Coronavirus (COVID-19)?

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, WVE stock has increased by 13.4% and is now trading at $9.21.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Wave Life Sciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Wave Life Sciences.

What stocks does MarketBeat like better than Wave Life Sciences?

Wall Street analysts have given Wave Life Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Wave Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Wave Life Sciences' next earnings date?

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Wave Life Sciences.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) announced its quarterly earnings results on Monday, November, 9th. The company reported ($0.86) EPS for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.13. Wave Life Sciences had a negative return on equity of 401.32% and a negative net margin of 1,562.01%.
View Wave Life Sciences' earnings history.

What price target have analysts set for WVE?

7 brokers have issued twelve-month price targets for Wave Life Sciences' shares. Their forecasts range from $10.00 to $27.00. On average, they expect Wave Life Sciences' stock price to reach $19.14 in the next year. This suggests a possible upside of 107.8% from the stock's current price.
View analysts' price targets for Wave Life Sciences.

Who are some of Wave Life Sciences' key competitors?

Some companies that are related to Wave Life Sciences include Cryoport (CYRX), Y-mAbs Therapeutics (YMAB), Aurinia Pharmaceuticals (AUPH), Dicerna Pharmaceuticals (DRNA), Madrigal Pharmaceuticals (MDGL), Rocket Pharmaceuticals (RCKT), Trillium Therapeutics (TRIL), Mersana Therapeutics (MRSN), Revance Therapeutics (RVNC), Heron Therapeutics (HRTX), Stoke Therapeutics (STOK), Arcus Biosciences (RCUS), NGM Biopharmaceuticals (NGM), CytoDyn (CYDY) and Keros Therapeutics (KROS).
View all competitors.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

Who are Wave Life Sciences' key executives?

Wave Life Sciences' management team includes the following people:

Dr. Paul B. Bolno M.B.A., M.D., MBA, Pres, CEO & Director (Age 46, Pay $881.53k)
Dr. Chandra Vargeese, Chief Technology Officer (Age 59, Pay $564.52k)
Dr. Michael A. Panzara M.P.H., M.D., MPH, Chief Medical Officer and Head of Therapeutics Discovery & Devel. (Age 53, Pay $597k)
Mr. David G. Gaiero, Interim Chief Financial Officer (Age 42)
Mr. Kyle B. Moran, Sr. VP of Fin. & Operations (Age 49)
Kate Rausch, Head of Investor Relations
Ms. Linda Rockett J.D., Gen. Counsel
Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 42)
Mr. Jose Juves, Sr. VP of Corp. Affairs & Patient Advocacy
Dr. Kenneth Rhodes, Sr. VP of Therapeutics Discovery

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (5.13%), BlackRock Inc. (6.73%), Nantahala Capital Management LLC (4.88%), JPMorgan Chase & Co. (3.10%), Morgan Stanley (3.08%) and Sphera Funds Management LTD. (2.55%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Gregory L Verdine, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc.
View institutional ownership trends for Wave Life Sciences.

Which major investors are selling Wave Life Sciences stock?

WVE stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, AXA S.A., State Street Corp, Quantitative Systematic Strategies LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Michael A Panzara, and Paul Bolno.
View insider buying and selling activity for Wave Life Sciences.

Which major investors are buying Wave Life Sciences stock?

WVE stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Sphera Funds Management LTD., Nantahala Capital Management LLC, Hound Partners LLC, Voloridge Investment Management LLC, JPMorgan Chase & Co., BlackRock Inc., and Squarepoint Ops LLC.
View insider buying and selling activity for Wave Life Sciences.

How do I buy shares of Wave Life Sciences?

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $9.21.

How big of a company is Wave Life Sciences?

Wave Life Sciences has a market capitalization of $449.25 million and generates $15.98 million in revenue each year. The company earns $-193,640,000.00 in net income (profit) each year or ($5.72) on an earnings per share basis. Wave Life Sciences employs 301 workers across the globe.

What is Wave Life Sciences' official website?

The official website for Wave Life Sciences is www.wavelifesciences.com.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings